Overview

Efficacy and Safety Study of MAX-002 Suppository Versus Placebo and Active Medicine in Mild to Moderate Ulcerative Proctitis

Status:
Terminated

Trial end date:
2011-09-30

Target enrollment:

Participant gender:

Summary

This is a prospective, multicenter, double-blind (DB), controlled, randomized, parallel group comparison Phase 3a study to evaluate the efficacy and safety of new mesalamine suppositories (MAX-002) as compared to placebo and active medicine after 6 weeks of treatment in adults with mild to moderate ulcerative proctitis (UP).

Phase:

Phase 3

Details

Lead Sponsor:

Axcan Pharma
Forest Laboratories

Treatments:

Mesalamine